神经系统疾病治疗技术平台 - 公司正在开发用于感知和治疗神经系统疾病的创新技术平台[137] - 公司的首个产品针对胰腺癌患者的疼痛进行治疗，但该技术平台有潜力应用于多种神经系统疾病[138] - 公司的感知导管已在动物模型中成功识别特定神经信号并确认治疗后信号终止[140] - 公司正准备进行首次人体试验以缓解胰腺癌相关疼痛，并计划将感知和治疗技术结合进行关键性临床试验[140] 许可协议 - 公司于2024年7月与RF Innovations公司签订许可协议,获得其Apex 6射频消融发生器的非独家许可[141] 研发费用 - 2024年第二季度,公司的研发费用同比增加159%至95.4万美元,主要用于临床试验计划和开发[144] 融资需求 - 公司预计需要额外融资约4000万美元来完成临床试验并推进产品商业化[149] - 公司目前的现金储备预计可维持运营至2025年第二季度[147] 员工补偿 - 公司已与关键员工签订协议,一旦被终止将获得1.1-1.6百万美元的补偿[154]

财务业绩 - 2025财年第一季度收入为[数据未提供][1] - 公司对未来业绩前景和指引未提供具体信息[1] 运营亮点 - 公司在2024年6月30日结束的2025财年第一季度公布了财务业绩和最新运营亮点[10] - 用户数据方面未提供具体数字[1] 新发展 - 新产品和新技术研发、市场扩张和并购、其他新策略等方面未提及[1]

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a ...

THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. About Autonomix Medical, Inc. For more information, visit autonomix.com and connect with the Company on ...

Live webcast on Wednesday, July 24th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Of ...

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDAcleared ablation technology from RF Innovations, Inc. For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. Ab ...

For the segment, Brad Hauser, Chief Executive Officer of Autonomix, discussed the Company's recently announced definitive agreement with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property underlying its Apex 6 Radiofrequency Generator and what this agreement means for the Company's development program. We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pa ...

文章核心观点 - 公司的一款用于治疗胰腺癌疼痛的医疗设备在临床试验中取得积极结果 [1][2] - 公司与RF Innovations签署了许可知识产权的最终协议,预计将于本月底完成 [3] - 公司股票在前一交易日大涨130%,成交量大幅增加 [4] - 受前一交易日大涨影响,公司股票在本交易日下跌16.7% [5] 公司概况 - 公司是一家处于发展阶段的医疗设备公司 [1] - 公司专注于开发用于治疗胰腺癌疼痛的医疗设备 [2] - 公司的设备采用射频消融技术来减轻胰腺癌患者的疼痛 [2] 股票表现 - 公司股票在前一交易日大涨130%,成交量大幅增加 [4] - 受前一交易日大涨影响,公司股票在本交易日下跌16.7% [5] - 本交易日公司股票成交量仍低于日均成交量 [6] 其他 - 文章还提到了其他公司的股票动态,但与本文核心内容无关 [7][8]

Per the release, Autonomix intends to leverage the technology in its strategic therapeutic units to enhance value for its pipeline. "This transaction represents a significant step forward for the development and commercialization of our innovative technology platform and can potentially simplify our regulatory strategy, as the Apex 6 Generator is already FDA-cleared in pain management," stated President and CEO Brad Hauser. At the same time, Autonomix is a speculative enterprise. The company made its public ...